# Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis

> **NCT02966834** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 147 (actual)

## Conditions studied

- Cholestasis

## Interventions

- **DRUG:** Placebo
- **DRUG:** GSK2330672

## Key facts

- **NCT ID:** NCT02966834
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-11
- **Primary completion:** 2020-04-15
- **Final completion:** 2020-04-15
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2021-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02966834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02966834, "Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02966834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*